Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer

被引：33

作者：

Ferraldeschi, R. ^{[1
]}

Pezaro, C. ^{[2
,3
]}

Karavasilis, V. ^{[4
]}

de Bono, J. ^{[2
,3
]}

机构：

[1] Inst Canc Res, Div Canc Therapeut, Signal Transduct & Mol Pharmacol & Clin Pharmacol, Sutton SM2 5NG, Surrey, England

[2] Inst Canc Res, Sutton SM2 5PT, Surrey, England

[3] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England

[4] Aristotle Univ Thessaloniki, Dept Med Oncol, GR-54006 Thessaloniki, Greece

来源：

ANNUAL REVIEW OF MEDICINE, VOL 64 | 2013年 / 64卷

关键词：

abiraterone acetate; enzalutamide (MDV3100); CYP17; inhibitors; CRPC; resistance; CIRCULATING TUMOR-CELLS; ANDROGEN-RECEPTOR GENE; I CLINICAL-TRIAL; STEROID-SYNTHESIS; PHASE-II; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; PLUS PREDNISONE; END-POINTS; INHIBITOR;

D O I：

10.1146/annurev-med-121211-091605

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Suppression of gonadal androgens by medical or surgical castration remains the mainstay of treatment for patients with advanced prostate cancer. However, the response to treatment is not durable, and transition to a "castration-resistant" state is invariable. Recent advances in our understanding of the androgen receptor signaling pathway have led to the development of therapeutic strategies to overcome castration resistance. This article reviews current concepts and challenges behind targeting continued androgen receptor signaling in castration-resistant prostate cancer and provides an overview of recently completed and ongoing clinical trials of novel hormonal agents, with a focus on abiraterone acetate and enzalutamide (MDV3100).

引用

页码：1 / 13

页数：13

共 73 条

[1] Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor [J].

Andersen, Raymond J. ;

Mawji, Nasrin R. ;

Wang, Jun ;

Wang, Gang ;

Haile, Simon ;

Myung, Jae-Kyung ;

Watt, Kate ;

Tam, Teresa ;

Yang, Yu Chi ;

Banuelos, Carmen A. ;

Williams, David E. ;

McEwan, Iain J. ;

Wang, Yuzhou ;

Sadar, Marianne D. .

CANCER CELL, 2010, 17 (06) :535-546

[2]

[Anonymous], J CLIN ONCOL S

[3] Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Mills, I. G. ;

Fisher, G. ;

Flohr, P. ;

Reid, A. ;

Edwards, S. ;

Kovacs, G. ;

Berney, D. ;

Foster, C. ;

Massie, C. E. ;

Fletcher, A. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

BRITISH JOURNAL OF CANCER, 2008, 99 (02) :314-320

[4] Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer [J].

Attard, G ;

Belldegrun, AS ;

de Bono, JS .

BJU INTERNATIONAL, 2005, 96 (09) :1241-1246

[5] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[6] Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Auchus, Richard J. ;

Hughes, Beverly A. ;

Cassidy, Amy Mulick ;

Thompson, Emilda ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Dowsett, Mitch ;

Arlt, Wiebke ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (02) :507-516

[7] Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break? [J].

Attard, Gerhardt ;

Cooper, Colin S. ;

de Bono, Johann S. .

CANCER CELL, 2009, 16 (06) :458-462

[8] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[9] Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[10] Molecular genetics of prostate cancer: emerging appreciation of genetic complexity [J].

Barbieri, Christopher E. ;

Demichelis, Francesca ;

Rubin, Mark A. .

HISTOPATHOLOGY, 2012, 60 (01) :187-198

← 1 2 3 4 5 6 7 8 →